Arcellx, Inc.

NasdaqGS ACLX

Arcellx, Inc. Dividends Paid for the Trailing 12 Months (TTM) ending September 30, 2024: USD 0.00

Arcellx, Inc. Dividends Paid is USD 0.00 for the Trailing 12 Months (TTM) ending September 30, 2024, a 0.00% change year over year. Dividends paid is cash paid to shareholders as a distribution of profits.
  • Arcellx, Inc. Dividends Paid for the Trailing 12 Months (TTM) ending September 30, 2023 was USD 0.00, a 0.00% change year over year.
  • Arcellx, Inc. Dividends Paid for the Trailing 12 Months (TTM) ending September 30, 2022 was USD 0.00, a 0.00% change year over year.
  • Arcellx, Inc. Dividends Paid for the Trailing 12 Months (TTM) ending September 30, 2021 was USD 0.00.
Key data
Date Dividends Paid Capital Expenditure Other Financing Activities Net Cash Used Provided By Financing Activities
Market news
Loading...
NasdaqGS: ACLX

Arcellx, Inc.

CEO Mr. Rami Elghandour
IPO Date Feb. 4, 2022
Location United States
Headquarters 25 West Watkins Mill Road
Employees 130
Sector Health Care
Industries
Description

Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.

Similar companies

BMEA

Biomea Fusion, Inc.

USD 4.15

0.00%

VTYX

Ventyx Biosciences, Inc.

USD 1.94

-0.51%

DAWN

Day One Biopharmaceuticals, Inc.

USD 11.16

-3.46%

AMLX

Amylyx Pharmaceuticals, Inc.

USD 3.13

-1.57%

NUVL

Nuvalent, Inc.

USD 72.39

0.74%

StockViz Staff

January 15, 2025

Any question? Send us an email